AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
2min chapter
Graham Collins, MBBS, on New Agents, Prognostic Models in Hodgkin Lymphoma
The HemOnc Pulse
ABVD Brintoxinab
Graham: Does the RATL have any significance whatsoever if you are going to AAVD plus Brintoxinab? Graham: The bottom line is I don't think it does. We actually proposed doing a trial of a response adapted AAVD Brint toxin approach, but we never really stood a chance for it being funded. He says he would struggle to see a role for ABVD if that were available.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode